Immunoglobulins Market Report 2026

The immunoglobulins market size has grown rapidly in recent years. It will grow from $20.32 billion in 2025 to $22.52 billion in 2026 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to growing prevalence of immunodeficiency diseases, increasing autoimmune disorder cases, rise in hospital infrastructure, technological advancements in plasma fractionation, expanding awareness about antibody therapies.

The immunoglobulins market size is expected to see rapid growth in the next few years. It will grow to $34.52 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to advancements in personalized medicine, development of novel monoclonal antibodies, increased home-based subcutaneous therapies, expansion of biotechnology and research centers, growing government support for immunotherapy programs. Major trends in the forecast period include personalized immunoglobulin therapy, increasing adoption of subcutaneous delivery methods, rising demand for ivig in autoimmune disorders, expansion of rare immunodeficiency treatments, growth in monoclonal antibody research.

The increasing healthcare expenditure is anticipated to drive the growth of the hyperphosphatemia treatment market in the coming years. Hyperphosphatemia treatment includes therapies and medications designed to lower elevated phosphate levels in the blood, a condition commonly observed in patients with chronic kidney disease and other related disorders. Higher healthcare spending enables wider access to these treatments, supports research and development of advanced therapeutic options, and enhances overall patient management approaches. For example, in November 2023, the Canadian Institute for Health Information, a Canada-based health information organization, reported that total healthcare spending in Canada was projected to reach $344 billion in 2023, equivalent to $8,740 per capita. This represents a 2.8% increase compared to 2022, when healthcare spending grew by only 1.5%, highlighting a significant recovery in healthcare investment. As a result, rising healthcare expenditure is contributing to the expansion of the hyperphosphatemia treatment market.

Major companies operating in the immunoglobulins market are focusing on the development of innovative products, such as intravenous immunoglobulins, to expand their customer base, increase sales, and drive revenue growth. For example, in September 2024, GC Biopharma, a South Korea-based biotechnology company, introduced ALYGLO (Immune Globulin Intravenous, Human-stwk) 10% Liquid in the U.S. market for the treatment of primary humoral immunodeficiency (PI) in adults aged 17 years and older. The product is now accessible to patients through specialty pharmacies. This launch is notable because the U.S. is the largest immunoglobulin market worldwide, valued at approximately $11.6 billion. GC Biopharma targets $50 million in ALYGLO sales during its first year, with plans to grow this figure to $300 million by 2028. This aggressive growth approach includes collaborations with major U.S. pharmacy benefit managers and specialty pharmacies, which play a key role in the effective distribution of immunoglobulin therapies.

In July 2024, Biogen Inc., a US-based biotechnology company, acquired Human Immunology Biosciences (HI-Bio) for an undisclosed amount. Through this acquisition, Biogen obtained HI-Bio’s lead asset, felzartamab, a fully human anti-CD38 monoclonal antibody under development for indications including IgA nephropathy (IgAN), primary membranous nephropathy (PMN), and antibody-mediated rejection (AMR) in transplant recipients, thereby strengthening Biogen’s immunology and immunoglobulin-related disease pipeline. Human Immunology Biosciences is a US-based company specializing in the development of fully human monoclonal antibodies.

Major companies operating in the immunoglobulins market are Baxter International Inc., CSL Behring LLC, Grifols S. A., Octapharma AG, China Biologic Products Holdings Inc., Kedrion SpA, LFB SA, Biotest AG, Sanquin Blood Supply Foundation, ADMA Biologics Inc., Option Care Health Inc., Shanghai RAAS Blood Products Co. Ltd., Antibody Solutions, Bio Products Laboratory Ltd., Immunovant Inc., Kamada Ltd., Emergent BioSolutions Inc., Fresenius Kabi AG, GlaxoSmithKline plc, Pfizer Inc., Roche Holding AG, Samsung Bioepis Co. Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Limited.

North America was the largest region in the immunoglobulins market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoglobulins market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the immunoglobulins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the immunoglobulins market by increasing the cost of imported plasma-derived products and advanced biopharmaceutical equipment, particularly affecting intravenous and subcutaneous immunoglobulin segments. Regions such as North America and Europe, which import high volumes of raw plasma materials, are most impacted. While the tariffs have raised production costs and slowed supply chains, they have also encouraged local manufacturing initiatives and investment in domestic biopharmaceutical capabilities, potentially enhancing long-term self-reliance and innovation in immunoglobulin therapies.

The immunoglobulins market research report is one of a series of new reports that provides immunoglobulins market statistics, including immunoglobulins industry global market size, regional shares, competitors with a immunoglobulins market share, detailed immunoglobulins market segments, market trends and opportunities, and any further data you may need to thrive in the immunoglobulins industry. This immunoglobulins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Immunoglobulins are glycoproteins, commonly referred to as antibodies, that are produced by plasma cells, a type of white blood cell. They are essential to the immune response, as they specifically recognize and bind to particular antigens, such as viruses or bacteria, and help facilitate their elimination.

The primary types of immunoglobulin products include IgG, IgA, IgM, IgE, and IgD. Immunoglobulin G (IgG) serves as the main mediator of humoral immunity in extracellular fluids, including blood, lymph, and saliva. Immunoglobulins are administered through intravenous and subcutaneous routes and are used in the treatment of conditions such as hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency disorders, myasthenia gravis, idiopathic thrombocytopenic purpura (ITP), and others.

The immunoglobins market consists of sales of antibodies, glycoproteins, and antigens. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.